The American Neurological Association’s 150th Annual Meeting held in Baltimore last week was a milestone meeting celebrating 150 years of progress, discovery, advances in science, and the remarkable work of academic neurologists and neuroscientists over the past century and a half. The meeting—ANA2025—featured outstanding plenary sessions, professional development workshops, interactive lunch workshops, special interest groups, cross-cutting special interest groups, the celebrated poster hall, satellite symposia, and several opportunities to network and connect with colleagues and friends.

Dr. Michelle Johansen of Johns Hopkins University School of Medicine, immediate past chair of the ANA Education Innovation Committee, engaged with meeting attendees to learn more about their experience at ANA2025 and what they think about the ANA. Listen in as meeting attendees share their insights, meeting highlights, and enthusiasm for the ANA during Dr. Johansen’s boots on the ground interactions with them. From the Presidential Symposium to the closing sessions, learn about ANA2025, the science and research shared, and the reactions of those who were in Baltimore to experience it.

Tune into the latest podcast from the American Neurological Association (ANA), ANA Investigates: 75 Years of NINDS. This year marks the 75th anniversary of the National Institute of Neurological Disorders and Stroke (NINDS)—an opportunity to reflect on the institute’s past achievements and look ahead to the future of neurological research.

This month, ANA Investigates welcomes Dr. Walter Koroshetz, Director of NINDS, in conversation with Dr. Adeline Goss, Neurohospitalist at Highland Hospital. Dr. Koroshetz joined the institute in 2007 as Deputy Director and became Director in 2015. Before joining the NINDS, he served as Vice Chair of Neurology, Director of Stroke and Neurointensive Care Services at Massachusetts General Hospital, and neurologist in the MGH Huntington’s Disease Clinic.

Tune in as they discuss highlights from the NINDS’s 75-year history and explore what lies ahead for neurological research and innovation.

• Guest: Walter J. Koroshetz, MD, FANA Director National Institute of Neurological Disorders and Stroke
• Interviewer: Adeline Goss, MD Neurohospitalist Highland Hospital
• Disclosures: None

Today we’ll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?

Our guest today is Dr.  Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.

References:

• https://www.nature.com/articles/s41598-024-79918-7

Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi